Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

GILEAD SCIENCES : Ex-dividend day for

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/12/2019 EDT

A dividend is removed today from Gilead Sciences's share.



© Factset 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
10:25aGRAPHIC - TAKE FIVE : Super Saturday, Super Mario
RE
10/15New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio
DJ
10/15GILEAD SCIENCES INC : Change in Directors or Principal Officers, Financial State..
AQ
10/15GILEAD SCIENCES : Names Andrew Dickinson Chief Financial Officer
DJ
10/15GILEAD SCIENCES : Appoints Andrew Dickinson as Chief Financial Officer
BU
10/10GILEAD SCIENCES : Galapagos See Efficacy in Advanced Rheumatoid Arthritis Study
DJ
10/10GILEAD SCIENCES : to Release Third Quarter 2019 Financial Results on Thursday, O..
BU
10/08GILEAD SCIENCES : Submits New Drug Application for Filgotinib for the Treatment ..
BU
10/07Gilead Sciences Names Merdad Parsey Chief Medical Officer
DJ
10/07GILEAD SCIENCES : Appoints Merdad Parsey, MD, PhD as Chief Medical Officer
BU
More news
Financials (USD)
Sales 2019 22 346 M
EBIT 2019 11 666 M
Net income 2019 4 272 M
Finance 2019 649 M
Yield 2019 3,88%
P/E ratio 2019 17,7x
P/E ratio 2020 11,4x
EV / Sales2019 3,65x
EV / Sales2020 3,60x
Capitalization 82 206 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 79,88  $
Last Close Price 64,91  $
Spread / Highest target 46,4%
Spread / Average Target 23,1%
Spread / Lowest Target -7,56%
EPS Revisions
Managers
NameTitle
Daniel O'Day Chairman & Chief Executive Officer
Robin L. Washington CFO, Chief Accounting Officer & Executive VP
George Pratt Shultz Director-Emeritus
Gayle Edlund Wilson Independent Director
John Francis Cogan Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES3.77%82 611
VERTEX PHARMACEUTICALS6.26%45 680
REGENERON PHARMACEUTICALS-19.26%32 998
WUXI APPTEC CO., LTD.68.13%20 570
GENMAB32.08%13 649
NEUROCRINE BIOSCIENCES, INC.35.63%8 869